Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
1st: who does this guy work for? 2nd: what is his ratings record?
You have 25 total posts on Ihub. This is your first post here EVER. We know what your agenda is. LOL
F@ck cramer!
$OGEN none that I know of. They just expanded a collaboration with Intrexon($XON). http://yhoo.it/1B32ELi I like the chart and the fact that R. Kirk holds over 9 million shares through Third Security. LLC.
These are usually envious pissed off people who missed the boat.
LOL too funny.
That's the correct way to invest in any stock.
alzheimer
$OGEN $1.69 R. Kirk owns 9,839,221 shares.
Check our $OGEN $1.65+ 5.83%
That's all I needed to hear!
Did you sell $RXII?
$CPRX $4.84+ 8%
Baker Bros own over 11% of company
May 11, 2015
Catalyst Pharmaceuticals Announces First Quarter 2015 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., May 11, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2015.
"This quarter we have been working to advance regulatory and commercial affairs and are moving closer to initiating the submission of our rolling NDA to the FDA next quarter for Firdapse® for the symptomatic treatment of LEMS," said Patrick J. McEnany, Catalyst's Chief Executive Officer. "This past quarter we made important strides on our commercial infrastructure, significant progress with our pipeline, and also strengthened our cash position."
Mr. McEnany added, "We recently reported that we held a productive pre-NDA meeting with the FDA and believe that our full clinical and non-clinical data packages provide acceptable support for a complete submission of an NDA for Firdapse®. We are working closely with the FDA on a pathway to include certain types of Congenital Myasthenic Syndromes (CMS) in the initial label upon approval in LEMS and also continuing our ongoing expanded access program which provides access to Firdapse® for patients with LEMS and CMS at no cost."
2015 Business Achievements to Date:
Confirmatory pre-NDA meeting with FDA regarding Firdapse® for LEMS
Raised $34.9 million, net of expenses, in a public offering of shares of common stock
Orphan Drug Designation of Firdapse® for treatment of Congenital Myasthenic Syndromes
Richard J. Daly and Donald A. Denkhaus appointed to Board of Directors
Development and advancement of comprehensive commercialization and pre-launch plan
Enrollment in expanded access program which allows LEMS and CMS patients early access to Firdapse®
Recently presented Phase 3 trial results at the annual meeting of the American Academy of Neurology (AAN) in Washington, D.C.
Upcoming 2015 Milestones:
Initiate rolling NDA for Firdapse for the treatment of LEMS in Q3 with anticipated completion of NDA submission during Q4
Announce topline results from a Phase 1(b) multiple dose safety and tolerance study for CPP-115 in Q3
Top-line results during this quarter expected from Mt. Sinai academic investigator sponsored study evaluating CPP-109 (Vigabatrin), as a surrogate for CPP-115, for the treatment of Tourette's disorder
Financial Results
For the quarter ended March 31, 2015, Catalyst reported a GAAP net loss of $5,410,259, or 7 cents per basic and diluted share, compared to a GAAP net loss of $3,811,119, or 7 cents per basic and diluted share, for the same period in 2014. Excluding non-cash expense of $1,180,278 attributable to the change in fair value of liability-classified warrants, Non-GAAP1 net loss was $4,229,981 or 6 cents per basic and diluted share for the first quarter of 2015. In comparison, Non-GAAP1 net loss for the first quarter of 2014 was $3,475,605, or 6 cents per basic and diluted share, which excludes non-cash expense of $335,514 attributable to the change in fair value of liability-classified warrants.
Research and development expenses for the first quarter of 2015 were $2,349,552 compared to $2,748,683 in the first quarter of 2014. Research and development expenses decreased when compared to the same period in 2014 as we decreased activities related to our completed Phase 3 trial for Firdapse®. However, we expect that our research and development spend for the rest of the year will increase significantly as we prepare for and submit our NDA for Firdapse® and as we increase activities in other ongoing studies and trials.
General and administrative expenses for the first quarter of 2015 totaled $1,942,363 compared to $759,682 in the first quarter of 2014. The increase when compared to the same period in 2014 is primarily due to an increase in pre-commercialization expenses and headcount, as we prepare for the future commercialization of Firdapse®.
As a development-stage specialty pharmaceutical company, Catalyst had no revenues in either the first quarter of 2015 or the first quarter of 2014.
At March 31, 2015, Catalyst had cash and cash equivalents, certificates of deposit and short-term investments of $71.5 million and no debt. This includes proceeds from our February 2015 offering in which we sold 11.5 million shares of our common stock, and raised net proceeds of approximately $34.9 million. We believe that these resources give us sufficient runway through anticipated approval and subsequent product launch of Firdapse®, assuming approval in 2016.
More detailed financial information and analysis may be found in the Company's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission (SEC), May 11, 2015.
_________________________
Thanks jbemm. I think a lot of people needed to hear this.
Do you have a link for this info?
He does that often.
No body worrying here just discussing MMs and flippers.
That's MMs working on it. Between the MMs and flippers the price has come down today. Word about this stock has definitely gotten around the boards and no doubt draws the flippers in.
Flippers are bringing it down.
Ok what is it that's so big coming for $CPRX?
Yes. Everything was being sold. Just the market today. $CARA has p2 topline data for CR 845 around 7/31/15.
I agree.
$TPIV .96-.96 support.
$SNGX needs more buyers than sellers to go up. Lot of sellers today.
That's a loaded statement. LOL
good luck with it. I'll wait, seems like it might have a lot of overhead resistance from traders chasing it on day of news and being stuck in it
(TBIO) Transgenomic Stock Spikes After Announcing Launch of Six New Cancer Tests
By
Tony Owusu
Follow
| 06/22/15 - 10:56 AM EDT
NEW YORK (TheStreet) -- Transgenomic (TBIO - Get Report) shares are up 14.21% to $2.09 on heavy volume in market trading on Monday after the global biotechnology company announced plans to launch up to six new lab-based cancer tests this year.
The tests will target actionable mutations in melanoma, lung cancer and colorectal cancer.
"We are ahead of schedule in commercializing our pipeline of laboratory-based cancer tests to meet the growing demand for targeted and personalized cancer treatments," said CEO Paul Kinnon.
The company said that it plans to release two or three new single and panel tests per quarter for the remainder of this year, while giving preference to the two most prevalent cancers, colorectal and lung.
TheStreet Ratings team rates TRANSGENOMIC INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:
"We rate TRANSGENOMIC INC (TBIO) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself."
Thanks. ;~)
$SNGX been climbing back up since 10:30 from a low of 2.16.
$TPIV Even though its trading it is halted according to my Fidelity broker.
Yeah I can see that but it's not showing a value in my brokerage account.
I use Fidelity for $PIRS, showing -100%.
Same here. I also use Schwab but have no $PIRS in it.
kei, ditto in my account. Showing as a negative $4000 though.
ron what's up with $PIRS? Will it get a new symbol on uplist?
$TPIV they will not let this go under $1, they want to uplist.